LONDON (AP) – AstraZeneca says it has applied for authorization to market in Europe a drug combining low-dose aspirin with its best-selling ulcer drug Nexium.
The pharmaceutical company said Friday that the product, called Axanum, is designed for heart patients who develop gastric disorders from taking low-dose aspirin by itself.
On Tuesday, AstraZeneca said the U.S. Food and Drug Administration has asked for more information about Axanum, delaying the company’s hopes of selling the product in America.
Date: June 4, 2010
Source: Associated Press
Filed Under: Drug Discovery
